Concepedia

Author

Christine Rojas

The University of Texas MD Anderson Cancer Center

Also Known As

CHRISTINE ROJAS, Christine Rojas, Rojas, Christine

67

Publications

621

Citations

11

H-Index

36

Concepts

All Affiliations

The University of Texas MD Anderson Cancer CenterWalter Reed National Military Medical CenterInova Health SystemHospital del SalvadorUniformed Services University of the Health Sciences
CR

About

Christine Rojas is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, obstetrics, and ovarian cancer.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

88

2

Engineering

1

1

43

3

Public Health

1

1

25

4

Cell Biology

1

1

43

5

Molecular Medicine

1

1

20

Christine Rojas

×

10

Publications

497

Citations

10

H-Index

YearCitations

Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial

Jörge E. Cortes, Jane F. Apperley, Elza Lomaia,

Blood

2021

185

Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer

Sanghoon Lee, Li Zhao, Christine Rojas,

Cell Reports

2020

133

Extensive three-dimensional intratumor proteomic heterogeneity revealed by multiregion sampling in high-grade serous ovarian tumor specimens

Allison L. Hunt, Nicholas W. Bateman, Waleed Barakat,

iScience

2021

43

Racial disparities in uterine and ovarian carcinosarcoma: A population-based analysis of treatment and survival

Christine Rojas, Chunqiao Tian, Matthew A. Powell,

Gynecologic Oncology

2020

25

Effect Of Gender And Lifestyle Behaviors On BMI Trends In A Sample Of The First State’s Undergraduate Population

Malcolm J. D’Souza, Karri-Jo E. Walls, Christine Rojas,

American Journal of Health Sciences (AJHS)

2015

23

Diffuse Large B-Cell Lymphoma in Chile: The Impact of Combined CHOP Plus Rituximab in the Public Health System

María Elena Cabrera, Camila Peña, Pilar León,

JCO Global Oncology

2022

22

Interim analysis (IA) of OPTIC: A dose-ranging study of three ponatinib (PON) starting doses.

Jörge E. Cortes, Elza Lomaia, Anna Turkina,

Journal of Clinical Oncology

2020

20

Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors

Kwong‐Kwok Wong, Nicholas W. Bateman, Chun Wai Ng,

Journal of Translational Medicine

2022

19

Three-Year Update from the Optic Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib

Jörge E. Cortes, Michael W. Deininger, Elza Lomaia,

Blood

2022

15

Analysis of Patterns of Patient Compliance After an Abnormal Pap Smear Result

Christine Rojas, Ming Zhou, Harry J. Khamis,

Journal of Lower Genital Tract Disease

2013

12

Page 1